Ultima-HGH Fragment 176-191: Compound Profile
HGH Fragment 176-191 is a synthetic peptide comprising amino acids 176-191 from the C-terminal region of human growth hormone. This 16-amino acid sequence represents the specific fragment researchers investigate for its distinct molecular properties separate from full-length growth hormone. The peptide maintains a molecular weight of approximately 1815.08 g/mol and demonstrates unique binding characteristics in laboratory studies. Ultima Peptides manufactures this research compound at 2mg concentration, providing researchers with standardised material for peptide metabolism investigations. Academic institutions frequently examine this fragment’s interaction with cellular receptors and its role in lipolytic pathway research. The compound’s isolated nature allows for precise study of specific growth hormone mechanisms without the complexity of the complete 191-amino acid protein structure. Researchers at Stroid UK Shop have access to this high-purity peptide for controlled laboratory environments.
Laboratory Applications
Research institutions utilise HGH Fragment 176-191 in metabolic pathway studies, particularly examining its interaction with adipocyte cell cultures. The fragment’s selective activity profile makes it valuable for isolating specific growth hormone receptor mechanisms from broader endocrine effects. Cell culture experiments demonstrate the peptide’s ability to bind to growth hormone receptors while exhibiting different signalling cascades compared to full-length hormone. Biochemical assays investigate the fragment’s role in lipolytic enzyme activation and fatty acid oxidation pathways. Researchers studying growth hormone biology examine this compound’s unique properties within the broader peptides category. The 2mg concentration provides sufficient material for multiple experimental protocols and dose-response studies. Comparative studies often pair this fragment with other growth hormone analogues from our HGH Fragment collection. Advanced peptide researchers also examine its stability characteristics and degradation pathways under various storage conditions. Some investigations explore its potential interactions with other peptide compounds available in our comprehensive research chemical inventory.
Technical Specifications
| Parameter | Specification |
|---|---|
| Peptide Sequence | 176-191 C-terminal fragment of hGH |
| Molecular Weight | ~1815.08 g/mol |
| Concentration | 2mg per vial |
| Purity | Research grade |
| Form | Lyophilised powder |
| Storage | -20°C (lyophilised), 2-8°C (reconstituted) |
| Solubility | Water-soluble when reconstituted |
| Stability | Use within 30 days after reconstitution |
Research Compliance
HGH Fragment 176-191 2mg from Ultima Peptides is manufactured exclusively for in-vitro research purposes and scientific investigation. This peptide is not intended for human consumption, therapeutic use, or any application outside controlled laboratory environments. Researchers must maintain appropriate storage conditions and handle the compound according to institutional safety protocols. The product requires proper laboratory training and adherence to peptide research guidelines. All research applications should follow established academic and regulatory standards for peptide investigation.
